Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.

Flonoltinib maleate, within the range of 0.008-1 μM for 2 hours, reduces p-FLT3 levels in a dose-dependent manner [1]. Additionally, flonoltinib maleate at concentrations of 5-100 nM for 2 hours exhibits a dose-related induction of apoptosis and significantly arrests the cell cycle at the G1/G0 phase, reaching 85% at 100 nM in MV4-11 cells [1].

Administered orally at doses of 30 and 60 mg/kg/day over a period of 14 days, Flonoltinib maleate demonstrates notable antitumor activity [1].